Form 4: InMed Pharmaceuticals Executive Reports Stock Option Conversion
SEC Form 4 Filing
Eric C. Hsu, Sr. VP at InMed Pharmaceuticals, reports the conversion of employee stock options into common shares.
Summary
- Eric C. Hsu, a Senior VP at InMed Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- The transaction involved the conversion of employee stock options into common shares on March 4, 2024.
- Hsu converted options for 309 common shares.
- Following the reported transaction, Hsu beneficially owns 52,545 common shares directly.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard reporting of stock option conversion.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects a change in the number of shares held by an executive.
Key Dates
| Date | Description |
|---|---|
| 03/04/2019 | Date exercisable for employee stock options |
| 03/04/2024 | Date of transaction: conversion of employee stock options to common shares |
| 03/04/2024 | Expiration date for employee stock options |
| 03/05/2024 | Date of signature for the Form 4 filing |
Keywords
Form 4, Beneficial Ownership, Stock Options, InMed Pharmaceuticals, Equity, Transaction, Securities, INM, Hsu
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.